Incidence of Clostridium difficile in Patients with Antibiotic Associated Diarrhea
,
Abstract
Background: This study was performed to determine the magnitude of Clostridioides difficile
infection (CDI) in a tertiary care hospital in patients with antibiotic associated diarrhea (AAD) and to
study the risk factors associated with this disease.
Methods: A descriptive study was conducted in the department of Microbiology in a tertiary care
hospital during December 2019 to May 2021. Stool samples were collected from patients with signs
and symptoms of AAD who had been consuming antibiotic or anticancer drugs durng six weeks before
the sampling. The samples were subjected to C. difficile glutamate dehydrogenase (GDH) enzyme and
CD toxin A & B detection by Enzyme Linked Fluorescent Assay (ELFA). Patient’s demographic
features and clinical details were noted and statistically correlated with the test results.
Results: Among the total 70 samples tested 20 (28%) were positive for GDH alone and 12 (17%) were
positive for both GDH and CD toxin A and B. Fluoroquinolones was a significant risk factor in the
study. Sepsis and colitis was found to have significant association with C.difficile infection in our study.
The crude mortality rate was 17%.
Conclusion: Prompt and precise diagnosis and knowledge about the risk factors of CDI helps in
effective management and prevention of CDI.
2. Hall IC, O'toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Children 1935;49(2):390-402.
3. Davies AH, Roberts AK, Shone CC, et al. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem J 2011;436(3):517-26.
4. Pépin J, Valiquette L. Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004; 171:466-72.
5. Fernández-García L, Blasco L, López M, et al. Clostridium difficile Infection: Pathogenesis, Diagnosis and Treatment. Clostridium difficile: A Comprehensive Overview. IntechOpen 2017:57.
6. Fenner L, Widmer AF, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008; 46(1):328-30.
7. Sachu A, Dinesh K, Siyad I, et al. A prospective cross-sectional study of detection of Clostridium difficile toxin in patients with antibiotic associated diarrhoea. Iran J Microbiol 2018; 10(1):1.
8. Lee YC, Wang JT, Chen AC, et al. Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J Microbiol Immunol Infec 2012; 45(4):287-95.
9. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infec Dis 2018; 66(7):e1-48.
10. Mitchell BG, Gardner A. Mortality and Clostridium difficile infection: a review. Antimicr Resis Infec Cont 2012; 1(1):1-6.
11. Tillotson GS, Tillotson J. Clostridium difficile-a moving target. Med Rep 2011;3.
12. Katyal R, Vaishnavi C, Singh K. Faecal excretion of brush border membrane enzymes in patients with Clostridium difficile diarrhoea. Ind J Med Microbiol 2002; 20(4):178-82.
13. Vishwanath S, Singhal A, D'Souza A, et al. Clostridium difficile infection at a tertiary care hospital in south India. J Assoc Physi Ind 2013; 61(11):804-6.
14. Wilcox MH, Mooney L, Bendall R, et al. A case–control study of community-associated Clostridium difficile infection. J Antimic Chem 2008 Aug 1; 62(2):388-96.
15. Singhal T, Shah S, Tejam R, et al. Incidence, epidemiology and control of Clostridium difficile infection in a tertiary care private hospital in India. Ind J Med Microbiol 2018; 36(3):381-4.
16. Kumar GV, Uma BM. Clostridium difficile: a neglected, but emerging pathogen in India. Arch Clin Microbiol 2015; 1:6.
17. Patel UC, Wieczorkiewicz JT, Tuazon J. Evaluation of advanced age as a risk factor for severe Clostridium difficile infection. J Clin Gerontol Geri 2016; 7(1):12-6.
18. Fomda A. revalence of C. difficile in patients with antibiotic associated diarrhea in a tertiary care hospital. Inter J 2014; 2(6):762-6.
19. Eliakim-Raz N, Fishman G, Yahav D, et al. Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case–control study. Euro J Clin Microbiol Infec Dis 2015; 34(6):1201-5.
20. Kamthan AG, Bruckner HW, Hirschman SZ, Agus SG. Clostridium difficile diarrhea induced by cancer chemotherapy. Archives Inter Med 1992; 152(8):1715-7.
21. Neemann K, Freifeld A. Clostridium difficile–associated diarrhea in the oncology patient. J Onco Pract 2017; 13(1):25-30.
22. Feuerstadt P, Boules M, Stong L, e al. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 2021; 9:2050312120986733.
23. McDonald EG, Milligan J, Frenette C, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Inter Med 2015; 175(5):784-791.
24. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults. Cochrane Database Systems Rev 2017;3.
| Files | ||
| Issue | Vol 12 No 1 (2024) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/jmb.v12i1.15016 | |
| Keywords | ||
| Antibiotic Associated Diarrhea Clostridium difficile Glutamate Dehydrogenase Toxin. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
